ZYPREXA RELPREVV
LOE Approachingolanzapine pamoate
NDAINTRAMUSCULARSUSPENSION, EXTENDED RELEASE
Approved
Dec 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 7m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYPREXA RELPREVV is an extended-release intramuscular suspension of olanzapine pamoate, an atypical antipsychotic indicated for maintenance treatment of schizophrenia and bipolar I disorder. The drug works by antagonizing dopamine and serotonin receptors in the central nervous system, providing symptom control with dosing every 2-4 weeks.
$0.004BPart D
LOE ApproachingThe product is approaching loss of exclusivity, signaling that brand team focus is shifting toward defending market share and preparing for generic competition rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
Started Apr 2006
524 enrolled
Schizophrenia
Career Relevance
Working on ZYPREXA RELPREVV offers exposure to mature product management, payer negotiations, and generic defense strategies in psychiatry, but limited innovation or launch experience. This role is best suited for professionals seeking expertise in post-patent lifecycle management and value-based care in mental health.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.